Mild COVID-19 symptoms despite treatment with teriflunomide and high-dose methylprednisolone due to multiple sclerosis relapse
Nora Möhn, Firas Saker, Viktoria Bonda, Gesine Respondek, Marcus Bachmann, Matthias Stoll, Mike P. Wattjes, Martin Stangel, Thomas Skripuletz
Topics & Concepts
TeriflunomideMultiple sclerosisMethylprednisoloneMedicineNeurologyCoronavirus disease 2019 (COVID-19)NeuroradiologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakAnesthesiaInternal medicineFingolimodPsychiatryVirologyDiseaseOutbreakInfectious disease (medical specialty)Multiple Sclerosis Research StudiesPeripheral Neuropathies and DisordersLong-Term Effects of COVID-19